Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Centogene NV
CNTGF
Healthcare
Centogene N.V., is a commercial company. The company focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The company's...
pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Company's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (OTCQB:CNTGF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 14, 2023 6:30am
New Press Release - CENTOGENE Regains Compliance With Nasdaq Listing Requirements
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has received notifications from the Nasdaq...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 12, 2023 7:30am
New Press Release - CENTOGENE Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort
Results Published in European Journal of Human Genetics Demonstrate Unprecedented Insights to Accelerate Potential Treatment Options Inclusion of 602 patients from 47 countries represents the world’s largest and most heterogeneous Niemann-Pick type C1 disease (NPC1) cohortStudy identified 287...
read article.
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 02, 2023 5:00am
New Press Release - Lifera and CENTOGENE, Enter Strategic Collaboration - Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing
Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly owned by the Public Investment Fund (PIF) based in Riyadh.JV focuses on providing state-of-the-art multiomic testing services to patients, health systems...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 30, 2023 4:30pm
New Press Release - CENTOGENE Announces Approval of All Resolutions Tabled at 2023 Annual General Meeting
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 30, 2023 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company’s Annual General...
read article.
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jun 28, 2023 10:53am
CNTG .... N.H.O.D
Who'dda thunk
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Jun 28, 2023 10:17am
RE:CNTG..... More Bagholders needed
Way to go......N.H.O.D
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jun 28, 2023 10:09am
CNTG..... More Bagholders needed
Cheers !
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jun 27, 2023 10:58am
CNTG.... Start the drumroll ; )
This is the last hurrah..... it better rally now or it's tats up for Bonzo Cheers !
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jun 27, 2023 10:07am
CNTG....don't get suckered into this
No volume
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jun 27, 2023 10:03am
CNTG..... Chump news release
Your done like dinner !!!! Back to where you started
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jun 27, 2023 9:54am
CNTG..... a breath of life ?
Make note: Volume is decreasing rapidly Watchout below
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jun 27, 2023 9:51am
CNTG ...in PB mode
Support at $1.06....final support also Has to hold and rally or it's the waterfall to where it all started Cheers !
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jun 27, 2023 8:58am
CNTG...early a.m runner on NR this a.m
On watch.... $1.16
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 16, 2023 6:25pm
New Press Release - CENTOGENE Reports Full Year 2022 Financial Results
Full Year 2022 total revenues with double-digit growth of 12% at €47.5 million, in line with prior guidanceSignificant expansion of gross profit margin from 32% to 42% and ongoing cost control resulted in significant improvement of net resultsBoth Pharma and Diagnostics segments positioned for...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 05, 2023 6:30am
New Press Release - CENTOGENE to Participate in Upcoming Conferences in May
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 05, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for May 2023. CENTOGENE representatives are...
read article.
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden